Unknown

Dataset Information

0

Beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension.


ABSTRACT: Numerous studies have demonstrated that beta(1)- and beta(2)-adrenergic receptor gene (ADRB1 and ADRB2) variants influence cardiovascular risk and beta-blocker responses in hypertension and heart failure. We evaluated the relationship between ADRB1 and ADRB2 haplotypes, cardiovascular risk (death, nonfatal myocardial infarction (MI), and nonfatal stroke), and atenolol-based vs. verapamil sustained-release (SR)-based antihypertensive therapy in 5,895 coronary artery disease (CAD) patients. After an average of 2.8 years, death rates were higher in patients carrying the ADRB1 Ser49-Arg389 haplotype (hazard ratio (HR) 3.66, 95% confidence interval (95% CI) 1.68-7.99). This mortality risk was significant in patients randomly assigned to verapamil SR (HR 8.58, 95% CI 2.06-35.8) but not atenolol (HR 2.31, 95% CI 0.82-6.55), suggesting a protective role for the beta-blocker. ADRB2 haplotype associations were divergent within the treatment groups but did not remain significant after adjustment for multiple comparisons. ADRB1 haplotype variation is associated with mortality risk, and beta-blockers may be preferred in subgroups of patients defined by ADRB1 or ADRB2 polymorphisms.

SUBMITTER: Pacanowski MA 

PROVIDER: S-EPMC2675574 | biostudies-literature | 2008 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension.

Pacanowski M A MA   Gong Y Y   Cooper-Dehoff R M RM   Schork N J NJ   Shriver M D MD   Langaee T Y TY   Pepine C J CJ   Johnson J A JA  

Clinical pharmacology and therapeutics 20080709 6


Numerous studies have demonstrated that beta(1)- and beta(2)-adrenergic receptor gene (ADRB1 and ADRB2) variants influence cardiovascular risk and beta-blocker responses in hypertension and heart failure. We evaluated the relationship between ADRB1 and ADRB2 haplotypes, cardiovascular risk (death, nonfatal myocardial infarction (MI), and nonfatal stroke), and atenolol-based vs. verapamil sustained-release (SR)-based antihypertensive therapy in 5,895 coronary artery disease (CAD) patients. After  ...[more]

Similar Datasets

| S-EPMC3462355 | biostudies-literature
| S-EPMC9520289 | biostudies-literature
| S-EPMC7275696 | biostudies-literature
| S-EPMC3398943 | biostudies-literature
| S-EPMC6279855 | biostudies-literature
| S-EPMC2662935 | biostudies-literature
| S-EPMC3678950 | biostudies-literature
| 2071360 | ecrin-mdr-crc
| S-EPMC2777849 | biostudies-other
| S-EPMC3071737 | biostudies-other